A5023080520- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Smoking Behavior and Cessation
- Tracheal and airway disorders
- Global Cancer Incidence and Screening
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Cancer Risks and Factors
- Air Quality and Health Impacts
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related Molecular Pathways
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Brain Metastases and Treatment
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Salivary Gland Tumors Diagnosis and Treatment
- Nutrition, Genetics, and Disease
- Medical Imaging and Pathology Studies
Inserm
1994-2022
Université Paris Cité
2012-2022
Hôpital Paris Saint-Joseph
2013-2022
Hôpital Saint Joseph
2011-2022
Toxicologie, Pharmacologie et Signalisation Cellulaire
2018-2022
Sorbonne Paris Cité
2014-2021
Assistance Publique – Hôpitaux de Paris
2004-2021
Hôpital Européen Georges-Pompidou
2021
Délégation Paris 5
2011-2020
Descartes (Belgium)
2018
The phase II prospective, noncomparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated patients with non-small cell lung cancer (NSCLC) asymptomatic untreated brain metastases to provide data this previously unexplored subgroup.Patients stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, untreated, received first-line (15 mg/kg) plus carboplatin (area under the curve ×6) paclitaxel (200...
Tumor somatic mutation analysis is part of the standard management metastatic lung cancer. However, physicians often have to deal with small biopsies and consequently challenging testing. Circulating free DNA (cfDNA) a promising tool for accessing tumor genome as liquid biopsy. Here, we evaluated next-generation sequencing (NGS) on cfDNA samples obtained from consecutive series patients screening range clinically relevant mutations.
•Vemurafenib monotherapy is effective for BRAFV600-mutated NSCLC.•Vemurafenib not BRAFnonV600-mutated a treatment option NSCLC patients when the dabrafenib/trametinib combination feasible or reimbursed.•Routine biomarker screening of should include BRAFV600 mutations. BackgroundBRAF mutations occurring in 1%–5% with non-small-cell lung cancer (NSCLC) are therapeutic targets these cancers but impact exact mutation on clinical activity unclear. The French National Cancer Institute (INCA)...
Background: An association between exposure to environmental tobacco smoke (ETS) and lung cancer risk has been suggested. To evaluate this possible better, researchers need more precise estimates of risk, the relative contribution different sources ETS, effect ETS on histologic types cancer. address these issues, we have conducted a case-control study in 12 centers from seven European countries. Methods: A total 650 patients with 1542 control subjects up 74 years age were interviewed about...
Cancer is a worldwide health problem. Personalized treatment represents future advancement for cancer treatment, in part due to the development of targeted therapeutic drugs. These molecules are expected be more effective than current treatments and less harmful normal cells. The discovery validation new targets foundation source these therapies. neurotensinergic system has been shown enhance progression various cancers such as pancreatic, prostate, lung, breast, colon cancer. It also...
Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort.KBP-2020 was a prospective cohort that included all diagnosed with LC 2020, nonacademic public hospital France. Patient and tumour characteristics were described compared similarly designed cohorts 2000 2010.In 82 centers 8,999 LC. The proportion of women increased: 34·6% (3114/8999) to, 24·3% (1711/7051) 16·0% (904/5667) 2010 (p<0·0001). non-smokers higher...
Despite advances in cancer therapy, mortality is still high except early-stage tumors, and screening remains a challenge. The randomized National Lung Screening Trial (NLST), comparing annual low-dose computed tomography (LDCT) chest X-rays, revealed 20% decrease lung-cancer-specific mortality. These results raised numerous questions. French intergroup for thoracic oncology the French-speaking group convened an expert to provide coherent outlook on modalities France.A literature review was...
Lung cancer in never-smokers (LCINS) (fewer than 100 cigarettes lifetime) is considered as a distinct entity and harbours an original molecular profile. However, the epidemiological features of LCINS Europe remain poorly understood. All consecutive newly diagnosed patients were included this prospective observational study by 75 participating centres during 14-month period. Each patient completed detailed questionnaire about risk factor exposure. Biomarker pathological analyses also...
// Mohamad Younes 1, * , Zherui Wu 1 2, Sandra Dupouy Audrey Mansuet Lupo 3 Najat Mourra 4 Takashi Takahashi 5 Jean François Fléjou Trédaniel 2 6 Régnard 7 Diane Damotte Marco Alifano Patricia Forgez UMRS U938, Hôpital Saint-Antoine 75012 Paris, France. 1007 Université Paris Descartes 45, rue des Saints-Pères 75270 cedex 06. Pathology Department, Descartes, Hôpitaux Universitaires Cochin Hôtel-Dieu Broca, 75014 Department Division of Molecular Carcinogenesis, Center for Neurological Diseases...
The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival resected non-small cell lung cancer (NSCLC) was investigated. Patients completely I, II or IIIA NSCLC were randomly allocated to receive subcutaneous 100 IU·kg −1 once a day for 12 weeks no treatment addition standard care. trial open-label blinded central adjudication study outcomes. primary...